Prelude Therapeutics Inc
No SEC Form 4 filings for $PRLD in the last 30 days.
See all $PRLD insider activity →Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.
Prelude Therapeutics (PRLD) reported Q2 2026 revenue of $5.7M and a net loss of $13.9M, or $0.14 per share. The company said it had $155.2M in cash and marketable securities as of June 30, 2026, projecting a runway into Q2 2028. R&D and G&A fell year over year. It also updated Phase 1 timelines for PRT13722 and PRT12396.
Over the past 7 days, alphai's AI scored 1 news story mentioning PRLD (Prelude Therapeutics Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PRLD coverage spans financial news, earnings and market movers.
Regulatory clearance adds credibility to pipeline.
Loss reduction and pipeline progress may attract short‑term buying.
Cash runway guidance into Q2 2028 and new clinical/regulatory milestones can shift near-term risk perception and financing expectations.
Near-term catalyst is IND-cleared Phase 1 initiation timing for PRT13722, alongside ongoing enrollment for PRT12396 and cash runway into Q2 2028.
This looks more like sentiment/flow than a new fundamental catalyst, so follow-through risk is higher.
alphai scores every news story that mentions PRLD with an AI model for sentiment and relevance, and aggregates insider trades from Prelude Therapeutics Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.
3 min readJourney Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.
3 min readPrelude Therapeutics (PRLD) reported Q2 2026 revenue of $5.7M and a net loss of $13.9M, or $0.14 per share. The company said it had $155.2M in cash and marketable securities as of June 30, 2026, projecting a runway into Q2 2028. R&D and G&A fell year over year. It also updated Phase 1 timelines for PRT13722 and PRT12396.
1 min readPrelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented
6 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readPrelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001678660 false 0001678660 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2
3 min readHC Wainwright & Co. analyst Robert Burns maintained a 'Buy' rating for Prelude Therapeutics (PRLD) and raised the price target to $8 from $5, a 60% increase. The positive outlook is based on the company's innovative pipeline in oncology. Despite a low GF Score™ of 37/100, indicating financial challenges, insider buying of $25.0 million in the past three months suggests confidence in the company's future.
3 min readPrelude Therapeutics announced preclinical data for PRT13722, a first-in-class, orally bioavailable KAT6A degrader for HR+/HER2- breast cancer. The data show potential for differentiated efficacy and safety, including complete responses as monotherapy in various models. Prelude aims to file an Investigational New Drug (IND) application by mid-2026 and initiate a clinical trial in the second half of 2026.
3 min readLOS ANGELES, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated ( "Prelude" or "the Company" ) ( NASDAQ:PRLD ) for violations of the ...
2 min readGS stands out as Zacks showcases how its stock picks like MU and PRLD delivered strong gains despite a shaky market.
3 min read
